Altamira Therapeutics (CYTO) Short Interest Ratio & Short Volume

Short interest is the volume of Altamira Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 145,200 shares of CYTO short. 6.57% of Altamira Therapeutics' shares are currently sold short. Learn More on Altamira Therapeutics' current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Altamira Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.57% of Altamira Therapeutics' floating shares are currently sold short.

Altamira Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 145,200 shares, an increase of 67.5% from the previous total of 86,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Altamira Therapeutics currently has issued a total of 1,580,000 shares. Some of Altamira Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Altamira Therapeutics currently has a public float of 2,210,000 shares.

6.57% of Altamira Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Altamira Therapeutics: Avenue Therapeutics, Inc. (3.26%), Dermata Therapeutics, Inc. (1.28%), Salarius Pharmaceuticals, Inc. (1.65%), Sonoma Pharmaceuticals, Inc. (0.30%), Clearmind Medicine Inc. (5.51%), CNS Pharmaceuticals, Inc. (0.31%), Notable Labs, Ltd. (0.08%), Onconetix, Inc. (0.31%), Galmed Pharmaceuticals Ltd. (1.49%), 60 Degrees Pharmaceuticals, Inc. (1.31%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling CYTO is an investing strategy that aims to generate trading profit from Altamira Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Altamira Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTO, twice per month. The most recent reporting period available is April, 30 2024.